ClinicalTrials.gg
RecruitingNCT07480356ADVANCED-3Updated Oct 6, 2026

Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer

A Phase 3 interventional study of TARA-002 and Investigator's Choice of Intravesical Chemotherapy in Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma and Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, sponsored by Protara Therapeutics. Recruiting at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Protara Therapeutics · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Oct 6, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
284
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn if TARA-002 can treat high-grade non-muscle invasive bladder cancer (NMIBC) in BCG-naïve adults 18 years of age or older.

The main questions it aims to answer are:

  • Can the study drug help participants with this type of cancer?
  • Is the study drug safe?
  • What are the side effects of the study drug?

Researchers will compare TARA-002 to chemotherapy to see if TARA-002 works to treat NMIBC.

02

Conditions studied

  • Bladder (Urothelial, Transitional Cell) Cancer
  • Non-Muscle Invasive Bladder Carcinoma
  • Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

Keywords

  • BCG-naive
  • Non-muscle invasive bladder Cancer
  • bladder cancer
  • carcinoma in situ
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's planned enrollment of 284 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Protara Therapeutics is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants 18 years of age or older at the time of signing
  • Participants who have voluntarily given written informed consent after the nature of the study has been explained according to applicable requirements prior to study entry
  • Central histologic confirmation of high-grade non-muscle invasive CIS (± Ta/T1) with active disease
  • Participants who are BCG naive, or participants who are BCG exposed and have not received intravesical BCG for at least 24 months prior to the most recent CIS diagnosis, or participants who received ≤2 doses of BCG within the 24 months prior to the most recent CIS diagnosis

Exclusion criteria

Exclusion Criteria:

  • Penicillin allergy (participants with a questionable history of allergy to penicillin will undergo penicillin blood allergy testing via central laboratory
  • Central confirmed variant histology
  • Concomitant prostatic or upper tract urothelial involvement per Investigator's assessment
  • Nodal and disease are excluded if they existed at any time (whether present or in the past)
  • Any history of ≥ T2 bladder cancer that existed at any point in time in the participant's history

For more information on eligibility criteria, please contact the Sponsor.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
284 participants (estimated)

Study arms

  • Experimental
    TARA-002 (Arm A)

    Drug: TARA-002

  • Active comparator
    Investigator's choice of intravesical chemotherapy

    Drug: Investigator's Choice of Intravesical Chemotherapy

Interventions

  • DrugTARA-002

    Drug pages: Picibanil · Lyophilized Inactivated Group A Streptococcus TARA-002

    Participants will receive 6 weekly instillations of TARA-002. Participants confirmed to have a CR at Week 12 will enter the maintenance treatment period and will receive 3 additional weekly instillations of TARA-002 every 3 months up to Month 19, and then 3 weekly doses at Month 25. Participants who are eligible for reinduction at Week 12 will receive 6 additional weekly instillations of TARA-002. Participants who undergo reinduction and are confirmed to have a CR at Week 24 will enter the maintenance regimen treatment period and will receive 3 weekly instillations of TARA-002 every 3 months up to Month 19, and then 3 weekly doses at Month 25.

  • DrugInvestigator's Choice of Intravesical Chemotherapy

    Participants will receive 6 weekly instillations of Investigator's choice of intravesical chemotherapy. Participants confirmed to have a CR at Week 12 will enter the maintenance regimen treatment period and will receive one intravesical instillation of Investigator's choice of intravesical chemotherapy every 1 month up to Month 25.

06

What researchers measure

Primary outcomes

  1. Incidence of high-grade complete response

    Incidence of high-grade complete response of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy determined by cystoscopy, urine cytology, and bladder biopsy (if applicable)

    Time frame: Month 6

Secondary outcomes

  1. Duration of high-grade complete response

    Duration of high-grade complete response of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy

    Time frame: Up to Month 60

  2. Treatment emergent adverse events

    Incidence and severity of treatment emergent adverse events (TEAEs) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy

    Time frame: Up to Month 60

  3. Treatment emergent serious adverse events

    Incidence and severity of treatment emergent serious adverse events (TESAEs) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy

    Time frame: Up to Month 60

  4. High-grade complete response rate

    High-grade complete response rate of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy determined by cystoscopy, urine cytology, and bladder biopsy (if applicable)

    Time frame: At Months 3, 9, 12, 15, 18, 21, 24, 27, 30, 36, 42, 48, 54, and 60

  5. High-grade complete response rate (CIS only)

    High-grade complete response rate of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy determined by cystoscopy, urine cytology, and bladder biopsy (if applicable) in sub-group of participants with CIS only

    Time frame: Month 6

  6. Event-free survival

    Event-free survival (EFS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy

    Time frame: Up to Month 60

  7. Recurrence-free survival

    Recurrence-free survival (RFS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy

    Time frame: Up to Month 60

  8. Progression-free survival

    Progression-free survival (PFS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy

    Time frame: Up to Month 60

  9. Disease-specific progression-free survival

    Disease-specific progression-free survival (DSPFS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy

    Time frame: Up ro Month 60

  10. Overall survival

    Overall survival (OS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy

    Time frame: Up to Month 60

  11. Disease-specific survival

    Disease-specific survival (DSS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy

    Time frame: Up to Month 60

  12. Time to cystectomy

    Time to cystectomy of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy

    Time frame: Up to Month 60

  13. Time to recurrence delayed cystectomy

    Time to recurrence delayed cystectomy of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy

    Time frame: Up to Month 60

  14. Time to progression

    Time to progression of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy

    Time frame: Up to Month 60

  15. Time to disease worsening

    Time to disease worsening of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy

    Time frame: Up to Month 60

07

Study locations

11 of 11 sites recruiting
  • East Valley Urology Center of Arizona
    Queen Creek, Arizona 85140, United States
    Recruiting
    • Use Central Contact · Contact
  • Arkansas Urology
    Little Rock, Arkansas 72211, United States
    Recruiting
    • Use Central Contact · Contact
  • Michael Oefelein Clinical Trials
    Bakersfield, California 93301, United States
    Recruiting
  • Urology of Greater Atlanta - Sandy Springs
    Atlanta, Georgia 30319, United States
    Recruiting
    • Use Central Contact · Contact
  • Renown Regional Medical Center
    St Louis, Missouri 63110, United States
    Recruiting
    • Use Central Contact · Contact
  • START - Carolinas
    Myrtle Beach, South Carolina 29572, United States
    Recruiting
    • Use Central Contact · Contact
  • Urology Partners of North Texas
    Arlington, Texas 76017, United States
    Recruiting
    • Use Central Contact · Contact
  • Urology Austin, LLC
    Austin, Texas 78745, United States
    Recruiting
    • Use Central Contact · Contact
  • Houston Metro Urology
    Houston, Texas 77027, United States
    Recruiting
    • Use Central Contact · Contact
  • Arenia - Ivano-Frankivsk
    Ivano-Frankivsk, 76018, Ukraine
    Recruiting
    • Use Central Contact · Contact
  • Arensia Kapitanivka - PPDS
    Kapitanivka, 08111, Ukraine
    Recruiting
    • Use Central Contact · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Apr 2028, 23 months after the start.

Of 119 industry-sponsored phase 3 interventional studies under Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's planned 23 months is below that.

Counting every sponsor, half of 202 studies reached it within 50 months; a quarter within 33 and three quarters within 84.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2026
First posted
Mar 18, 2026
StartActual
May 29, 2026
Primary completionEst.
Apr 2028
CompletionEst.
Nov 2032
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Urology Austin, LLC · Austin, United States
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    1 site added
    Show site
    • Urology Austin, LLC · Austin, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07480356
Lead sponsor
Protara Therapeutics
Responsible party
Sponsor
First posted
Mar 18, 2026
Start date
May 29, 2026
Primary completion
Apr 2028 (estimated)
Completion
Nov 2032 (estimated)
Last update
Oct 6, 2026

Study contacts

Chief R&D Officer
Contact
clinicaltrials@protaratx.com
16468440337

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Picibanil · Lyophilized Inactivated Group A Streptococcus TARA-002

Start the discussion